The Impact of Surgical Strategy and Rifampin on Treatment Outcome in Cutibacterium Periprosthetic Joint Infections.
Cutibacterium species
Propionibacterium species
antibiotic treatment
periprosthetic joint infections
rifampin
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 06 2021
15 06 2021
Historique:
received:
31
07
2020
pubmed:
11
12
2020
medline:
25
6
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
Cutibacterium species are common pathogens in periprosthetic joint infections (PJI). These infections are often treated with β-lactams or clindamycin as monotherapy, or in combination with rifampin. Clinical evidence supporting the value of adding rifampin for treatment of Cutibacterium PJI is lacking. In this multicenter retrospective study, we evaluated patients with Cutibacterium PJI and a minimal follow-up of 12 months. The primary endpoint was clinical success, defined by the absence of infection relapse or new infection. We used Fisher's exact tests and Cox proportional hazards models to analyze the effect of rifampin and other factors on clinical success after PJI. We included 187 patients (72.2% male, median age 67 years) with a median follow-up of 36 months. The surgical intervention was a 2-stage exchange in 95 (50.8%), 1-stage exchange in 51 (27.3%), debridement and implant retention (DAIR) in 34 (18.2%), and explantation without reimplantation in 7 (3.7%) patients. Rifampin was included in the antibiotic regimen in 81 (43.3%) cases. Infection relapse occurred in 28 (15.0%), and new infection in 13 (7.0%) cases. In the time-to-event analysis, DAIR (adjusted hazard ratio [HR] = 2.15, P = .03) and antibiotic treatment over 6 weeks (adjusted HR = 0.29, P = .0002) significantly influenced treatment failure. We observed a tentative evidence for a beneficial effect of adding rifampin to the antibiotic treatment-though not statistically significant for treatment failure (adjusted HR = 0.5, P = .07) and not for relapses (adjusted HR = 0.5, P = .10). We conclude that a rifampin combination is not markedly superior in Cutibacterium PJI, but a dedicated prospective multicenter study is needed.
Sections du résumé
BACKGROUND
Cutibacterium species are common pathogens in periprosthetic joint infections (PJI). These infections are often treated with β-lactams or clindamycin as monotherapy, or in combination with rifampin. Clinical evidence supporting the value of adding rifampin for treatment of Cutibacterium PJI is lacking.
METHODS
In this multicenter retrospective study, we evaluated patients with Cutibacterium PJI and a minimal follow-up of 12 months. The primary endpoint was clinical success, defined by the absence of infection relapse or new infection. We used Fisher's exact tests and Cox proportional hazards models to analyze the effect of rifampin and other factors on clinical success after PJI.
RESULTS
We included 187 patients (72.2% male, median age 67 years) with a median follow-up of 36 months. The surgical intervention was a 2-stage exchange in 95 (50.8%), 1-stage exchange in 51 (27.3%), debridement and implant retention (DAIR) in 34 (18.2%), and explantation without reimplantation in 7 (3.7%) patients. Rifampin was included in the antibiotic regimen in 81 (43.3%) cases. Infection relapse occurred in 28 (15.0%), and new infection in 13 (7.0%) cases. In the time-to-event analysis, DAIR (adjusted hazard ratio [HR] = 2.15, P = .03) and antibiotic treatment over 6 weeks (adjusted HR = 0.29, P = .0002) significantly influenced treatment failure. We observed a tentative evidence for a beneficial effect of adding rifampin to the antibiotic treatment-though not statistically significant for treatment failure (adjusted HR = 0.5, P = .07) and not for relapses (adjusted HR = 0.5, P = .10).
CONCLUSIONS
We conclude that a rifampin combination is not markedly superior in Cutibacterium PJI, but a dedicated prospective multicenter study is needed.
Identifiants
pubmed: 33300545
pii: 6029420
doi: 10.1093/cid/ciaa1839
pmc: PMC8427719
doi:
Substances chimiques
Anti-Bacterial Agents
0
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1064-e1073Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR056647
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Antimicrob Agents Chemother. 2012 Apr;56(4):1885-91
pubmed: 22252806
J Antimicrob Chemother. 2013 Mar;68(3):523-8
pubmed: 23115111
J Infect. 2011 Sep;63(3):229-35
pubmed: 21763722
PLoS One. 2018 Aug 20;13(8):e0202639
pubmed: 30125299
Knee Surg Sports Traumatol Arthrosc. 2016 Oct;24(10):3106-3114
pubmed: 26392344
Clin Infect Dis. 2011 Aug;53(4):334-40
pubmed: 21810745
Med Mal Infect. 2014 Jun;44(6):241-50
pubmed: 24656842
Int Orthop. 2016 May;40(5):913-8
pubmed: 26224611
Clin Infect Dis. 2012 Feb 1;54(3):393-407
pubmed: 22157324
Clin Infect Dis. 2018 Jan 6;66(1):54-63
pubmed: 29020266
Am J Med. 2006 Nov;119(11):993.e7-10
pubmed: 17071171
Acta Orthop. 2016 Feb;87(1):60-6
pubmed: 26414972
Science. 1999 May 21;284(5418):1318-22
pubmed: 10334980
Antimicrob Agents Chemother. 2011 Oct;55(10):4589-93
pubmed: 21825285
J Arthroplasty. 2018 Jul;33(7):2246-2250
pubmed: 29544969
J Bone Jt Infect. 2018 Nov 24;3(5):255-257
pubmed: 30533347
N Engl J Med. 2004 Oct 14;351(16):1645-54
pubmed: 15483283
Clin Infect Dis. 1992 Jun;14(6):1251-3
pubmed: 1623081
Health Technol Assess. 2019 Aug;23(38):1-92
pubmed: 31373271
J Bone Joint Surg Am. 1996 Apr;78(4):512-23
pubmed: 8609130
Antimicrob Agents Chemother. 2009 Mar;53(3):1142-8
pubmed: 19075065
Annu Rev Microbiol. 1987;41:435-64
pubmed: 3318676
Clin Infect Dis. 2008 Apr 15;46(8):1221-6
pubmed: 18444859
Clin Microbiol Infect. 2006 May;12(5):433-9
pubmed: 16643519
J Infect. 2007 Aug;55(2):119-24
pubmed: 17418419
J Shoulder Elbow Surg. 2018 Dec;27(12):2175-2182
pubmed: 30104101
J Clin Microbiol. 2016 Dec;54(12):3043-3049
pubmed: 27733637
BMC Musculoskelet Disord. 2019 Oct 22;20(1):467
pubmed: 31640638
Clin Microbiol Rev. 2014 Apr;27(2):302-45
pubmed: 24696437
Infection. 2004 Aug;32(4):222-8
pubmed: 15293078
Clin Infect Dis. 2008 Jun 15;46(12):1884-6
pubmed: 18462110
Wellcome Open Res. 2019 Jul 17;4:108
pubmed: 31930174
Anaerobe. 2015 Aug;34:116-9
pubmed: 25999299
Clin Infect Dis. 2013 Jan;56(1):e1-e25
pubmed: 23223583
Infection. 2013 Apr;41(2):431-7
pubmed: 22987291
J Antimicrob Chemother. 1997 Feb;39(2):235-40
pubmed: 9069545